Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Margo Bragg

Physician Assistant, Medical Fredericksburg, VA Physician Assistant

NPI 1255527404 CMS profile 10731711

120 Executive Center Pkwy, Fredericksburg, VA 22401

Open in the dashboard

General payments

$5,936

364 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margo Bragg of Fredericksburg, VA is reported in the CMS Open Payments database as having received $5,936 across 364 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,538 81
2024 General $1,491 80
2023 General $1,285 88
2022 General $1,025 73
2021 General $597 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margo Bragg
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Margo Bragg were reported at $1,538. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Margo Bragg Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $597 $156 $41–$563 $132
2022 $1,025 $185 $55–$649 $149
2023 $1,285 $199 $58–$717 $160
2024 $1,491 $206 $62–$740 $164
2025 $1,538 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,188 95 payments
  2. AstraZeneca Pharmaceuticals LP $953 51 payments
  3. Novo Nordisk Inc $542 28 payments
  4. Lilly USA, LLC $348 21 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $333 37 payments
  6. Abbott Laboratories $305 17 payments
  7. Pfizer Inc. $267 15 payments
  8. Otsuka America Pharmaceutical, Inc. $262 15 payments
  9. Astellas Pharma US Inc $235 9 payments
  10. Exact Sciences Corporation $230 10 payments
  11. Other $1,273 66 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,851 363 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $481 29 payments
  2. VRAYLAR $440 49 payments
  3. FARXIGA $403 20 payments
  4. Ozempic $394 19 payments
  5. RYBELSUS $371 18 payments
  6. BREZTRI $367 19 payments
  7. AIRSUPRA $343 16 payments
  8. XIFAXAN $333 37 payments
  9. TRULANCE $333 37 payments
  10. QULIPTA $333 20 payments
  11. Other $3,987 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

4,921

Median for Physician Assistant: 241

Drug cost

$369,442

Median for Physician Assistant: $4,110

Branded share of claims

20.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 43 $61,895
Ozempic Semaglutide Brand 41 $55,633
Farxiga Dapagliflozin Propanediol Brand 34 $33,821
Rybelsus Semaglutide Brand 14 $29,859
Januvia Sitagliptin Phosphate Brand 23 $25,393
Mounjaro Tirzepatide Brand 16 $21,629
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $18,541
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $17,700
Janumet Sitagliptin Phos/Metformin Hcl Brand 15 $15,274
Myrbetriq Mirabegron Brand 11 $13,311

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$99,174

Medicare's payments for the services billed

Medicare patients

530

Average age 76

Services billed

1,546

320 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 30%
Diabetes 26%
Atrial fibrillation 18%
Chronic kidney disease 15%
Cancer 15%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $83
  • Otsuka America Pharmaceutical, Inc. $59
$142 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $138
$138 — —
VRAYLAR
  • AbbVie, Inc. $98
$98 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $86
$86 — —
QULIPTA
  • AbbVie, Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

364 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record